P173
Low LDL-cholesterol goal attainment 4 months after ACS due to lack of adjustment in lipid lowering treatment: Results from DYSIS II

Extract

Background: The objective of the second Dyslipidemia International Study (DYSIS II) was to document use of lipid-lowering therapies (LLTs), LDL-C target value attainment (LDL-C <70 mg/dL) at the time of the acute event and at 4-months follow-up in patients with acute coronary syndrome (ACS).

Methods: The ACS cohort of DYSIS II included patients from 18 countries (8 Asian, 5 European, and 5 Middle East). Evaluations were performed at the time of admission, at discharge, and 120±15 days following the date of admission (the follow-up time point).

Results: Of the 3,867 patients enrolled, 2,521 were on LLT at admission. Most treated patients received statin monotherapy (89.8% at admission and 86.7% at follow-up). Few patients received combinations of statins with ezetimibe (4.1% at admission, 6.3% at follow-up) or other therapies (3.2% at admission, 3.6% at follow-up). Statin dose was increased during hospitalization for ACS but no further LLT-adjustment did take place afterwards. LDL-C <70mg/dl was achieved in 24.8% at admission and in 34.4% at follow-up. Chronic kidney disease (OR 1.52, 95% CI 1.09–2.13), diabetes (OR 1.33, 95% CI 1.08–1.64), and higher atorvastatin doses (OR 1.01, 95% CI 1.004–1.016) were predictors of LDL-C target attainment.